To determine the effect of exercise on the in vivo formation of circulating platelet aggregates in patients with severe coronary artery disease (CAD), platelet aggregate ratios (PAR) (normal 0.8-1.1) were measured immediately before and after treadmill exercise and 30 minutes after exercise in 17 CAD patients (group 1, mean age 55 years), 12 age-matched normal subjects (group 2), and 13 young normals (mean age 27 years, group 3). Coronary patients had lower resting PAR than group 3 (0.79 ± 0.05 vs 0.98 ± 0.03; p < 0.01), while group 2 had an intermediate value 0.86 4-0.04 (p > 0.05 vs CAD and group 3). Immediately after exercise, group I PAR declined from 0.79 i 0.05 to 0.53 ± 0.04 (p < 0.001), while groups 2 and 3 were unchanged (p > 0.05; both p < 0.001 vs group 1); 30 minutes after exercise, PAR in group 1 rose to 0.66 ± 0.05 (p < 0.05 vs pre-and immediately postexercise); groups 2 and 3 remained unchanged vs pre-and immediately postexercise (p > 0.05; both p < 0.001 vs group 1). Six group 1 patients received 1300 mg aspirin daily for 10 days and repeated the protocol. Resting PARs were unchanged (p > 0.05) from resting values without aspirin. The exercise-induced decline in PAR was attenuated by aspirin: without aspirin, 0.73 ± 0.02 preexercise to 0.54 ± 0.04 postexercise; with aspirin, 0.73 ± 0.03 to 0.82 ± 0.03 (p < 0.05 vs no aspirin). These data indicate that platelet aggregation occurs with exercise in CAD. In addition, these data suggest that aspirin exerts a significant inhibitory effect on exercise-induced platelet aggregation in CAD patients.
THROMBOEMBOLISM has been implicated in the pathogenesis of both myocardial infarction and sudden death by some workers;1 2 this has been disputed by others.3 Moreover, certain investigators have attributed a prominent role to platelets in the pathogenesis of atherosclerosis.1 4' 5 Thus, it has become important to better define abnormal platelet aggregation in patients with coronary disease. Current evidence suggests that intra-arterial platelet aggregation may occur spontaneously in vivo2' 6 and that platelet survival is reduced in patients with coronary artery disease.7 Pharmacologic agents that inhibit platelet aggregation normalize platelet survival. 8 9 Despite considerable interest in the role of platelets in the initiation of coronary thrombi, either transient or chronic, previous studies usually used in vitro techniques. Few investigators have studied the effect of exercise on platelet aggregation. In vivo platelet aggregates have been shown to be quite transient,'0 making it important to assay postexercise platelet aggregation with both an immediate and late postexercise measurement to avoid underestimating enhanced platelet aggregation. Finally, the effect of aspirin on platelet aggregation in coronary patients should be clarified.11
The present investigation was performed to define quantitatively whether platelet aggregates can be detected in blood drawn from the antecubital vein in patients with documented severe coronary artery disease at rest and in response to treadmill exercise. This investigation compared platelet aggregation ratios in coronary patients with those obtained in both agematched controls as well as young normal controls. In addition, the effect of a therapeutic course of aspirin on platelet aggregation before and immediately after exercise was evaluated in the coronary patients.
Methods and Materials

Study Population
The study group included 42 male patients and subjects. Seventeen patients, mean age 55.5 years (range 33-65 years), with symptomatic coronary artery disease constituted group 1. Twelve of the 17 group 1 patients underwent coronary arteriography; eight patients had stenoses (. 80%) of each of the three major coronary arteries, three patients had two-vessel disease and one patient had total occlusion of the left anterior descending coronary artery only. The remaining five patients had electrocardiographic evidence of transmural myocardial infarction. Twelve normal age-matched subjects, mean age 53 years (range 41-58 years), served as controls (group 2). Each subject in this group had a normal resting ECG, no history of heart disease and no major risk factor for coronary artery disease. Five of the age-matched control subjects had previously undergone coronary arteriography and had normal coronary arteries. An additional 13 subjects 24-29 years old (mean 27 years) also served as normal controls (group 3). All were in good health, with no history of heart disease or other serious medical illness. No participant in the investigation received a platelet-inhibiting drug for at least 2 weeks before the study.
Quantification of Platelet Aggregates
We used the method of Wu and Hoak to detect circulating platelet aggregates.'2 Venous blood was drawn from an antecubital vein in an identical manner from all study participants using a tourniquet in each. The blood (0.5 ml) was drawn into two separate siliconized syringes; syringe A contained 2 ml of buffered EDTA-formalin solution and syringe B contained 2 ml of buffered EDTA solution only. Solution A was prepared by mixing 1.5 parts 0.07 M Na2 EDTA, 2.5 parts 4% formalin, and 6.0 parts trisbuffered saline at a pH of approximately 7.4. Solution B was prepared by adding 1.5 parts Na2 EDTA (0.07 M) to 8.5 parts tris-buffered saline at a pH of 7.4.
The blood-solution mixtures were immediately transferred to silicon-coated plastic tubes and allowed to stand for 15 minutes at 22°C. The red cells were lysed using a Unopette containing ammonium oxalate and a phosphate buffer. The platelets were counted visually with a bright-line hemacytometer and a phasecontrast microscope. The results for each determination were expressed as a ratio:
Platelet aggregate ratio = Platelet count EDTA-formalin Platelet count EDTA The normal range in this investigation was 0.8-1.1.1'
Study Protocol
Blood was drawn for the initial platelet assay in the fasting state while at rest. Each patient then underwent graded, multistaged treadmill exercise using the Bruce protocol.14 Exercise was terminated in the group 1 patients at the onset of chest pain, exhaustion or upon obtaining 85% of maximal predicted heart rate. To insure a controlled standard hemodynamic stress, all subjects in groups 2 and 3 were required to achieve at least 85% of their maximal predicted heart rate to qualify for inclusion into the study. Blood was drawn for a second platelet aggregate ratio within the first minute after exercise and a third specimen was obtained 30 minutes after terminating the treadmill exercise test.
After completing the protocol, six patients in group 1 received aspirin (1300 mg/day) for 10 consecutive days. The protocol was then repeated.
Data were analyzed using the t test for paired and nonpaired values.
Results
During treadmill exercise, the coronary artery disease patients constituting group 1 achieved a mean maximal heart rate of 68% of their predicted maximum. In contrast, all subjects in groups 2 and 3 achieved at least 85% of their maximal predicted heart rate (mean 88%; group 1 vs group 2, p < 0.05; group 1 vs group 3, p < 0.05). In group 1, 12 of 17 (71%) patients demonstrated an ischemic electrocardiographic response to exercise defined as horizontal or downsloping ST-segment depression of . 0.1 mV for at least 0.08 second beyond the J point. None of the control subjects in groups 2 or 3 developed ischemic electrocardiographic alteration, (p < 0.05 vs group I).
At rest there was no difference (p > 0.05) in the mean platelet counts between the three groups. As previously reported, exercise increased the mean platelet count in each group.15 However, a comparison of the percent rise and mean count of the three groups revealed no difference (p > 0.05).
The mean platelet aggregate ratio in group 1 at rest before exercise was 0.79 i 0.05 (mean ± SEM) (range 1.05-0.29) (table 1). Nine of the 17 (53%) group 1 coronary patients had resting platelet aggregate ratios below the lower limits of normal. The average resting preexercise platelet aggregate ratio in the age-matched controls, group 2, was 0.86 ± 0.04 (1.02-0.64 range) (p > 0.05 vs group 1). Sixty-six percent of group 2 subjects had resting values within the normal range. The normal controls constituting group 3 had a resting mean platelet aggregate ratio value of 0.98 ± 0.03 (p < 0.01 vs group 1); all but one normal subject had resting values within the normal range.
Immediately after exercise, the mean platelet aggregate ratio in the group 1 coronary patients declined to 0.53 ± 0.04 (p < 0.001 vs group 1 preexercise) (table 1). The mean platelet aggregate ratios after exercise were similar (p > 0.05) in group 1 patients with and without exercise-induced electrocardiographic evidence of ischemia. In contrast, no significant (p > 0.05) reduction occurred with exercise in the mean platelet aggregate ratio in either groups 2 or 3 (table   1) .
Thirty minutes postexercise the mean platelet aggregate ratio in group 1 increased to 0.66 ± 0.05 (p < 0.05 vs group 1 immediately postexercise) but remained depressed compared to the preexercise value of 0.79 ± 0.05 (p < 0.05). At 30 minutes after exercise, the platelet aggregate ratios in groups 2 and 3 remained at preexercise levels, 0.83 + 0.05 and 1.0 ± 0.03, respectively (both p < 0.001 vs group 1; bothp > 0.05 vs their resting preexercise values) (table 1).
The findings in the six group 1 coronary patients who received aspirin 1300 mg/day for 10 consecutive days and then repeated the exercise protocol are summarized in table 2. The mean platelet aggregate ratio in the six aspirin-treated patients at rest and 30 minutes after exercise did not differ significantly (p > 0.05) from the baseline pre-aspirin determinations. However, the decrease in the mean platelet aggregate 63 VOL 61, No 1, JANUARY 1980 For definitions of groups 1, 2 and 3, see text.
ratio observed immediately following exercise was attenuated by aspirin therapy (table 2) .
Discussion
Our findings suggest that exercise will induce in vivo formation of circulating platelet aggregates in patients with severe coronary artery disease. Consistent with the findings of Wu and Hoak,'2 most (84%) of the control subjects in groups 2 and 3 had normal ratios at rest. Imnmediately postexercise, the young normals had normal values, as did 67% of the age-matched control subjects. However, four patients (33%) from this older control group had abnormal postexercise ratios that were consistent with platelet aggregate formation. Two of these four patients underwent coronary arteriography and were documented to have no coronary artery stenoses.
The aggregate ratios obtained from the patients with coronary artery disease consistently demonstrated the greatest degree of abnormality. Thus, at rest, nine of 17 (53%) of these patients had ratios below the lower limit of normal. While we can only speculate as to why such a large fraction of these patients had abnormal resting values, these data suggest that patients with severe coronary artery disease, some of whom have widespread vascular athero- tion. In addition, the platelet aggregate ratios were lower (p < 0.05) in the coronary patients at each measurement period than in the young controls and significantly lower (p < 0.05) than in the age-matched controls at the immediate and 30-minute postexercise measurement intervals. Prior attempts to define abnormal in vitro platelet aggregation after standardized exercise testing have yielded conflicting results. Yamazaki et al.l6 and Levites and Haft'7 found increased aggregation immediately after exercise testing in patients with coronary disease. However, other studies did not confirm these observations.'8 19 The reasons for the disparity in results is unclear; however, the interval from the completion of the exercise test to the time of phlebotomy may have differed between the various studies. Particularly noteworthy is the recent observation that aggregates will disaggregate within 6-10 minutes.10 Thus, the exercise-induced hyperaggreable state may be short-lived. This observation is supported in the present study by our findings that 30 minutes after exercise, the coronary patients uniformly had ratios that were higher than the immediate postexercise values and approximated the resting values. These data support the concept that enhanced aggregation is a transient phenomenon and that in vivo platelet aggregates are capable of relatively rapid disaggregation.
Normally, platelets do not aggregate spontaneously in vivo. However, if a suitable stimulus is present, aggregation can occur. Postulated mechanisms include exposure to collagen in atherosclerotic lesions;8' 20 platelet damage secondary to shear stress;2' post- obstructive luminal turbulence resulting in increased platelet-platelet interactions;'0 and enhanced or abnormal responsiveness to circulating catechol- 22 amines. As blood flow increases as a result of the hemodynamic response to exercise, each of these mechanisms would be enhanced and may cause the production of circulating aggregates in the coronary artery disease patients. Mehta et al. recently demonstrated that atrial pacing-induced tachycardia will increase platelet aggregation.23 Subclinical atherosclerotic lesions, which are beyond the limits of angiographic detection, or peripheral vascular disease, may also trigger one or several of the proposed mechanisms. This explanation may apply to several of the age-matched normals, some with normal coronary arteries, who developed platelet aggregates immediately after exercise.
Finally, we do not know if in vivo tests do indeed detect circulating platelet aggregates or if aggregates form after phlebotomy. It has been suggested that the method of Wu and Hoak may actually be detecting platelet hypersensitivity with consequent enhanced in vitro formation of platelet aggregates."' 24 Despite these unresolved questions, the technique does appear to clearly identify a population of abnormal platelets that occur in patients with vascular disease.
Of special importance in the present investigation is the effect of aspirin on the exercise-induced platelet aggregate ratio in patients with coronary artery disease. The decline in the mean aggregate ratio was attenuated by a 10-day course of aspirin (p < 0.05). These findings suggest that in certain patients with coronary artery disease, there is increased activity of the arachidonate pathway after exercise, which results in increased platelet aggregation. 25 
